𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma

✍ Scribed by Martin-Walter Welker; Stephan Zangos; Susanne Kriener; Christian Mönch; Stefan Zeuzem; Joerg Trojan

Book ID
107574740
Publisher
Springer US
Year
2010
Tongue
English
Weight
289 KB
Volume
41
Category
Article
ISSN
1941-6628

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Field-practice study of sorafenib therap
Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
✍ Massimo Iavarone; Giuseppe Cabibbo; Fabio Piscaglia; Claudio Zavaglia; Antonio G 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

on behalf of the SOFIA (SOraFenib Italian Assessment) study group A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib a

Multimodal image-guided tailored therapy
Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: Long-term survival in the experience of a single radiologic referral center
✍ Tito Livraghi; Franca Meloni; Alberto Morabito; Claudio Vettori 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB 👁 1 views

The best treatment policy for some patients with hepatocellular carcinoma (HCC) and compensated cirrhosis is still controversial. The aim of this study was to evaluate the long-term survival and related prognostic factors of patients with early and intermediate HCC (Liver Unit of Barcelona classific

Determination of the optimal model for e
Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy
✍ Teh-Ia Huo; Jaw-Ching Wu; Han-Chieh Lin; Fa-Yauh Lee; Ming-Chih Hou; Yi-Hsiang H 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

The model for end-stage liver disease (MELD) has been a prevailing system to prioritize cirrhotic patients awaiting liver transplantation. An "exceptional" MELD score of 20 and 24 points is assigned for stage T1 and T2 patients with small hepatocellular carcinoma (HCC), respectively. However, this s